Positron Emission Tomography with 18-Fluorodeoxyglucose in the Staging and Follow-up of Lymphoma in the Chest

Bangerter, Jörg Kotzerke Markus Markus

doi:10.1080/028418699432969

Cited by 77 publications

(4 citation statements)

References 33 publications

(34 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results are in concordance with the literature. Bangerter et al showed a sensitivity of 96% and a specificity of 94% with PET in lymphoma of the thorax in 89 consecutive patients [8]. However, FDG is not a tumor-specific tracer.…”

Section: Discussionmentioning

confidence: 99%

“…It can differentiate between scar tissue or active tumor tissue after treatment [6]. Many studies have shown the benefit of FDG PET in staging, restaging, and prediction of response to treatment in malignant lymphoma [7, 8]. The combination of metabolic and morphological imaging, using hybrid PET/CT scanners or software-based image fusion, is a promising technique that might overcome the limitations of each single modality [9–12].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Diagnostic Value of Software-Based Image Fusion of Computed Tomography and F18-FDG PET Scans in Patients with Malignant Lymphoma

Henninger

Putzer

Kendler

et al. 2012

The Scientific World Journal

View full text Add to dashboard Cite

Aim. The purpose of this study was to evaluate the accuracy of 2-deoxy-2-[fluorine-18]fluoro-D-glucose (FDG) positron emission tomography (PET), computed tomography (CT), and software-based image fusion of both modalities in the imaging of non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD). Methods. 77 patients with NHL (n = 58) or HD (n = 19) underwent a FDG PET scan, a contrast-enhanced CT, and a subsequent digital image fusion during initial staging or followup. 109 examinations of each modality were evaluated and compared to each other. Conventional staging procedures, other imaging techniques, laboratory screening, and follow-up data constituted the reference standard for comparison with image fusion. Sensitivity and specificity were calculated for CT and PET separately. Results. Sensitivity and specificity for detecting malignant lymphoma were 90% and 76% for CT and 94% and 91% for PET, respectively. A lymph node region-based analysis (comprising 14 defined anatomical regions) revealed a sensitivity of 81% and a specificity of 97% for CT and 96% and 99% for FDG PET, respectively. Only three of 109 image fusion findings needed further evaluation (false positive). Conclusion. Digital fusion of PET and CT improves the accuracy of staging, restaging, and therapy monitoring in patients with malignant lymphoma and may reduce the need for invasive diagnostic procedures.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Diagnostic Value of Software-Based Image Fusion of Computed Tomography and F18-FDG PET Scans in Patients with Malignant Lymphoma

Henninger

Putzer

Kendler

et al. 2012

The Scientific World Journal

View full text Add to dashboard Cite

show abstract

“…Among the nuclear modality imaging, positron emission tomography (PET) and single photon emission computed tomography (SPECT) having high detection sensitivity has been the most sought, for staging and follow up of solid tumors in patients in the clinics [44, 45]. Also, the vast choice of radionuclides and versatility of conjugation chemistries available for radiolabeling are yet another key advantage with nuclear modality imaging [46, 47].…”

Section: Molecular Imaging Systems In Cancermentioning

confidence: 99%

Image-Guided Nanosystems for Targeted Delivery in Cancer Therapy

Iyer

Amiji

2012

CMC

View full text Add to dashboard Cite

Current challenges in early detection, limitations of conventional treatment options, and the constant evolution of cancer cells with metastatic and multi-drug resistant phenotypes require novel strategies to effectively combat this deadly disease. Nanomedical technologies are evolving at a rapid pace and are poised to play a vital role in diagnostic and therapeutic interventions - the so-called “theranostics” – with potential to advance personalized medicine. In this regard, nanoparticulate delivery systems can be designed with tumor seeking characteristics by utilizing the inherent abnormalities and leaky vasculature of solid tumors or custom engineered with targeting ligands for more specific tumor drug targeting. In this review we discuss some of the recent advances made in the development of multifunctional polymeric nanosystems with an emphasis on image-guided drug and gene delivery. Multifunctional nanosystems incorporate variety of payloads (anticancer drugs and genes), imaging agents (optical probes, radio-ligands, and contrast agents), and targeting ligands (antibodies and peptides) for multi-pronged cancer intervention with potential to report therapeutic outcomes. Through advances in combinatorial polymer synthesis and high-throughput testing methods, rapid progress in novel optical/radiolabeling strategies, and the technological breakthroughs in instrumentation, such as hybrid molecular and functional imaging systems, there is tremendous future potential in clinical utility of theranostic nanosystems.

show abstract

“…Most of these sites (93%) were true positive with only one of seven additional findings on CT being positive [17]. A review of 89 consecutive patients comparing CT with PET found that PET had a sensitivity of 98%, a specificity of 94% and an overall accuracy 94% [18]. A subsequent study examining 81 patients with HL demonstrated a staging accuracy for PET of 96% compared with 56% for conventional imaging [19].…”

Section: Stagingmentioning

confidence: 99%